Brief: Sorrento Announces Publication Of A Series Of Novel Sars-Cov-2 Main Protease (MPRO) Inhibitors For Potential Treatment Of COVID-19 Patients Infected With SARS-COV-2 Variants Of Concern, Including Omicron
05/12/2021 19:31
Dec 5 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO ANNOUNCES PUBLICATION OF A SERIES OF NOVEL
SARS-COV-2
MAIN PROTEASE (MPRO) INHIBITORS FOR POTENTIAL TREATMENT OF
COVID-19 PATIENTS INFECTED WITH SARS-COV-2 VARIANTS OF CONCERN,
INCLUDING OMICRON
Source text for Eikon: ID:nGNX9fQkGs
Further company coverage: SRNE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20